Anti-tetanus Toxin Antibody Research Articles

The Role of the Gastrointestinal Tract in Toxigenic Clostridium tetani Infection: A Case-Control Study.

ABSTRACT.Tetanus arises from wound contamination with Clostridium tetani, but approximately one fifth of patients have no discernable entry wound. Clostridium tetani is culturable from animal feces, suggesting the gastrointestinal tract could be an endogenous reservoir or direct-entry portal, but human data are lacking. In this study of 101 Vietnamese adults with tetanus and 29 hospitalized control subjects, admission stool samples were cultured for C. tetani. Anti-tetanus toxin antibodies were measured by ELISA. Clostridium tetani toxigenicity was evaluated using polymerase chain reaction and sequencing. Toxigenic C. tetani was cultured from stool samples in 50 of 100 (50%) tetanus cases and 12 of 28 (42.9%) control subjects (P = 0.50), and stool samples of 44 of 85 (52.4%) tetanus cases with clinically identified wounds compared with 6 of 15 (47.6%) patients without clinically identified wounds (P = 0.28). Nine of 12 (75%) control subjects with toxigenic C. tetani in their stool samples lacked protective antibody concentrations. These findings fail to show evidence of an association between gastrointestinal C. tetani and tetanus infection, but emphasize the importance of increasing vaccination coverage.

Characterization and evaluation of the enzymatic activity of tetanus toxin submitted to cobalt-60 gamma radiation.

BackgroundTetanus toxin blocks the release of the inhibitory neurotransmitters in the central nervous system and causes tetanus and its main form of prevention is through vaccination. The vaccine is produced by inactivation of tetanus toxin with formaldehyde, which may cause side effects. An alternative way is the use of ionizing radiation for inactivation of the toxin and also to improve the potential immunogenic response and to reduce the post-vaccination side effects. Therefore, the aim of this study was to characterize the tetanus toxin structure after different doses of ionizing radiation of 60Co.MethodsIrradiated and native tetanus toxin was characterized by SDS PAGE in reducing and non-reducing conditions and MALD-TOF. Enzymatic activity was measured by FRET substrate. Also, antigenic properties were assessed by ELISA and Western Blot data.ResultsCharacterization analysis revealed gradual modification on the tetanus toxin structure according to doses increase. Also, fragmentation and possible aggregations of the protein fragments were observed in higher doses. In the analysis of peptide preservation by enzymatic digestion and mass spectrometry, there was a slight modification in the identification up to the dose of 4 kGy. At subsequent doses, peptide identification was minimal. The analysis of the enzymatic activity by fluorescence showed 35 % attenuation in the activity even at higher doses. In the antigenic evaluation, anti-tetanus toxin antibodies were detected against the irradiated toxins at the different doses, with a gradual decrease as the dose increased, but remaining at satisfactory levels.ConclusionIonizing radiation promoted structural changes in the tetanus toxin such as fragmentation and/or aggregation and attenuation of enzymatic activity as the dose increased, but antigenic recognition of the toxin remained at good levels indicating its possible use as an immunogen. However, studies of enzymatic activity of tetanus toxin irradiated with doses above 8 kGy should be further analyzed.

Chlorovirus Acceleration of Motor Neuron Disease in SOD1G93A Transgenic Mice may Clarify some of the Augmented anti-Chlorovirus Serology in Amyotrophic Lateral Sclerosis Patients

Abstract Infections and inflammatory responses may contribute to motor neuron diseases (MND), such as Amyotrophic Lateral Sclerosis (ALS). A portion of familial ALS is caused by polymorphic Superoxide Dismutase (SOD)1 gene (SOD1G93A). As chloroviruses (CV) infect macrophages inducing inflammatory cytokines, they may contribute to ALS. Moreover, ATCV-1 is one of several chlorovirus types that encodes its own SOD1. Thus we evaluated serum from human ALS patients compared with controls for antibody against ATCV-1. In addition, we i.c. injected saline or ATCV-1 into SOD1G93A-transgenic and C57Bl/6 control mice and assessed development of ALS-like MND. Sera from ALS patients and controls had antibody to ATCV-1. However, ALS patients had significantly greater IgG1 anti-ATCV-1 compared with controls. This was accompanied by elevated IL-6, IFN-γ, and anti-Tetanus toxin antibody, but not IL-17. SOD1G93A mice inoculated with ATCV-1 had significantly accelerated development of MND, including tail paralysis, hindlimb tucking, decreased righting reflex, and latency to fall in a hanging cage lid test, compared with saline injected SOD1G93A mice. Splenic T cells of SOD1G93A and control mice showed similar IFN-γ and IL-17 responses to anti-CD3/-CD28, while Foxp3 expression overall was significantly higher in T cells of SOD1G93A compared with control mice. Inoculation with ATCV-1 decreased Foxp3 expression in SOD1G93A T cells compared with mice not given ATCV-1. These results indicate that chloroviruses, ubiquitous in fresh waters worldwide, induce antibody responses in humans that are elevated in ALS and may accelerate MND in the SOD1G93A type of familial ALS. Funding was generously provided by the Stuart Nichols ALS Research Foundation.

Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate

Acute myeloid leukemia (AML) is a high-risk malignancy with overall poor outcomes across the age spectrum. Attempts to intensify cytotoxic chemotherapeutic regimens in recent decades have been limited by toxic acute and late effects, establishing the necessity of targeted therapy development. Immunotherapy is a highly promising treatment strategy in AML; however, its development has been limited as agents with potent anti-leukemic activity often confer significant hematopoietic toxicities. We previously reported the identification of an ideal potential immunotherapeutic target, mesothelin (MSLN), a cell surface protein expressed in 37% of childhood and young adult AML as well as older adult AML that, importantly, is absent in normal hematopoietic cells. Mesothelin is overexpressed in a number of solid tumors and has been studied as a target in solid tumors with various immunotherapeutic agents, including the antibody-drug conjugate (ADC) anetumab ravtansine (AR), comprised of an anti-MSLN antibody conjugated to the maytansinoid tubulin inhibitor DM4. We evaluated AR as well as a novel MSLN-targeted ADC for their ability to induce MSLN-directed cytotoxicity in several cell lines engineered to express MSLN.As we have previously reported, the leukemia cell line K562 transduced to overexpress MSLN (K562+MSLN) was highly sensitive to AR in vitro with an IC50 of 1.4 nM (Fig. 1a). Furthermore, AR was highly active in vivo in K562+MSLN xenograft-bearing mice. We sought to extend the study of AR's cytotoxicity in AML, to illustrate its potential as a therapeutic agent, in 3 additional AML cell lines, MV4;11, Kasumi-1, and Me-1, lentivirally-transduced to express MSLN, with cell-surface MSLN levels confirmed by flow cytometry. In vitro cytotoxicity assays demonstrated potent MSLN-dependent cytotoxicity of AR in MV4;11+MSLN cells with IC50 0.009 nM, compared to 1.9-3.8 nM in control experiments with parental cells or isotype control (IC) treatment (Fig. 1b). AR had limited MSLN-dependent activity in Kasumi-1+MSLN, with an IC50 of 28 nM, compared to 76-87 nM in controls (Fig. 1c) and no MSLN-dependent cytotoxicity in Me-1+MSLN, compared to controls (Fig. 1d). Previous reports suggest that DM4 is a substrate of the drug resistance protein P-glycoprotein (ABCB1). We evaluated drug resistance protein expression, including ABCB1, MRP1-6, LRP1, and BRCP, using RNASeq in representative AR-sensitive and AR-resistant cell lines, MV4;11 and Kasumi-1, respectively, and examined published RNASeq data for K562 and Me-1, and found that P-glycoprotein expression correlated with resistance to AR, measured by the IC50 (R2 = 0.995, p = 0.002).To optimize ADC targeting of MSLN in AML, we created a novel MSLN-targeted ADC using an alternative MSLN antibody with an alternative chemotherapeutic payload, pyrrolobenzodiazepine (PBD) dimer, and molecular linker (anti-MSLN-PBD) as well as 3 control compounds: an anti-MSLN ADC with a DM4 payload (anti-MSLN-DM4) and isotype controls comprised of anti-Tetanus toxin antibody conjugated to PBD (IC-PBD) or DM4 (IC-DM4). In vitro cytotoxicity assays in the 4 aforementioned MSLN+ leukemia cell lines revealed potent MSLN-dependent cell kill with the novel anti-MSLN-PBD compared to controls in all but Me-1+MSLN, with IC50 of 1.6 pM-8.3 nM (Fig. 1e-h). Notably, unlike AR, anti-MSLN-PBD was able to confer MSLN-dependent cytotoxicity in Kasumi-1+MSLN. Sensitivity to anti-MSLN-PBD was independent of P-glycoprotein expression.Mesothelin is a cell-surface protein previously recognized as an attractive immunotherapeutic target in solid tumors that is aberrantly expressed in a sizeable subset of AML patients of all ages, and herein we report successful targeting of MSLN in leukemia cells in vitro with antibody-drug conjugates. AR, an ADC well-tolerated in phase I testing for solid tumors, showed dramatic MSLN-dependent cytotoxicity in 2 cell lines at clinically-achievable doses. To optimize MSLN targeting in AML, we created a novel MSLN-targeted ADC with a PBD dimer payload, which conferred a high degree of MSLN-dependent cytotoxicity in vitro in 3 of 4 MSLN+ leukemia cell lines tested. Mesothelin-directed ADCs hold great promise for the treatment of MSLN+ AML across the age spectrum and warrant additional pre-clinical and clinical evaluation as potential novel immunotherapeutics for AML. DisclosuresNo relevant conflicts of interest to declare.

Key protection factors against tetanus: Anti-tetanus toxin antibody affinity and its ability to prevent tetanus toxin – ganglioside interaction

Antibodies capable to neutralize tetanus toxin (TeNT) are key factors in protection against tetanus disease. Although antibody-based therapeutics for treatment of tetanus exist on the market its production is tedious. Hence, the tetanus-specific antibodies preparation that could be easily produced in large scale in vitro would be beneficial. Monoclonal antibodies (MAbs) are considered for a long time as a reagent of choice, but the core drawback is how to select a MAb that would be safe in providing efficacious protection. In this study we have investigated the parameters crucial for a single MAb to be assigned as protective. Eight murine MAbs were characterized in vitro for their reactivity toward TeNT and assessed in vivo for protectiveness against TeNT intoxication. Correlation of in vitro and in vivo data has revealed that in vitro selection of MAb that is protective in vivo could be performed by a combination of two assays: the measurement of MAb affinity toward TeNT taking Ka 1 × 10(8) M(-1) as a threshold level, and the evaluation of its capability to prevent TeNT-ganglioside interaction. Single MAb could be taken into consideration as a potential therapeutic only if it has a capacity to completely inhibits TeNT-ganglioside complex formation.

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

BackgroundCD20 is a cell surface antigen commonly expressed on B-cell lineage, but is absent on hematopoïetic stem cells and plasma cells. Therefore, it has been postulated that its targeting should not significantly affect immunoglobulin serum concentrations. However, due to rapid and prolonged B-cell depletion, rituximab-based therapy has been shown to impair humoral response. In addition, protective serologic response to influenza vaccination in lymphoma patients in the 6 months following rituximab-containing regimen has been found to be particularly low1. Because the vast majority of adults individuals have been previously vaccinated against tetanus, we decided to analyse the impact of prolonged rituximab-based therapy on the immune protection rate against tetanus toxin in patients, and conducted in this aim a sub-analysis in follicular lymphoma (FL) patients treated into the PRIMA study.MethodsThe PRIMA study is a multicentre, phase III, randomized study in patients with advanced FL evaluating the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy, whose results have been previously published2. In a subset of patients, serum samples were prospectively collected and antitetanus toxin antibodies were measured at baseline, end of immunochemotherapy induction and end of maintenance period. Protective titer was defined as > 0.1 UI/mL according to standards. Statistical analysis aimed to determine if serum antitetanus antibodies titers significantly changed over time according to different phases of treatment, and if rituximab maintenance arm had a significant impact as compared to observation arm.ResultsOverall, 104 patients were evaluable for this subanalysis. Fifty-five percent were male. Median age was 57 (range, 27-80), 88.5% had Ann-Arbor stage III-IV disease. All patients had received R-CHOP induction. Among those patients, 56 were randomised into rituximab arm, 48 into observation arm. At baseline, median serum antitetanus antibodies titers in the overall population was 0.8 UI/mL (range, 0–8) and 89.4% of patients had protective titers. At the end of induction, among the 70 evaluable subjects, 90% had still a protective titer with a median of 0.7 UI/mL (range, 0-4), and at the end of maintenance period, among the 62 evaluable patients, 93% had still protective titer with a median of 0.8 (range, 0-3). When comparing the two arms, at the end of maintenance period, median serum antitetanus antibodies titer was 0.8 UI/mL in the rituximab arm, not significantly different from that in the observation arm (0.6 UI/mL) (p=0.17). At the end of the maintenance period, 100% of subjects had still protective titer in the rituximab arm versus 84.6% in the observation arm.ConclusionIn this subanalysis of 104 FL treated patients issued from the PRIMA study, rituximab-based induction and maintenance therapy did not significantly affect the immunisation rate against tetanus toxin in previously immunized patients. These results are in contrast with the poor serologic response rate obtained following rituximab-based therapy, emphasizing that common serum vaccinal titers should be controlled, and vaccination updated, when possible, before treatment initiation and the first rituximab administration.References1-Yri O, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011, 118 (6769 – 6771).2-Salles G, Seymour J, Offner F, et al. Rituximab maintenance for 2 years in patient with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377 (42-51). DisclosuresKarlin:Sandoz: Consultancy; celgene: Consultancy, Honoraria; Janssen: Honoraria. Delmer:Roche: Honoraria. Brice:Seattle Genetics, Inc.: Research Funding; Takeda Pharmaceuticals International Co.: Honoraria, Research Funding; Roche: Honoraria.

The seroepidemiology of tetanus in Catalonia, Spain

Titres of anti-tetanus toxin antibodies > or = 0.1 IU/ml were determined using an enzyme linked immunosorbent assay in representative samples of the juvenile and adult population of Catalonia. The prevalence obtained in 1,316 juveniles and 1,296 adults was 99.4 and 68.3%, respectively. In adults, the prevalence in males (76.5%) was higher (P < 0.001) than in females (61.7%), fell with increasing age and was higher in subjects born in Catalonia (72.5%) than in those born outside Catalonia (57.9%) (P < 0.001). These results show that routine vaccination of children is successful. In adults aged > or = 45 years, the prevalence is inadequate and efforts should be made to increase vaccination.

Tetanus nach Schürfwundenverletzung

A 80 year-old woman contracted an abrasion of her right forearm while gardening. 5 days later, dysphagia, trismus and a cramp of the right hand developed. On admission (8 days after the injury) cramps of the platysma and pharyngeal muscles were observed. A tetanus vaccination had not been carried out for years. Electrophysiologically a pathological masseter inhibitory reflex with a missing "silent period" was observed. The level of serum anti-tetanus-toxoid IgG antibodies was 0.03 IU/ml (definitively protective above 0.1 IU/ml). Free tetanus toxin was not detectable in the serum upon mouse challenge. The diagnosis of tetanus was made based on the typical symptoms and the serological susceptibility. On admission the wound was antiseptically cleaned and a bandage was applied. On the next day a debridement was performed. After taking a serum sample the patient was immunized against tetanus (active and passive). On the following two days the patient received a further dose of tetanus-antitoxin. The patient was treated with metronidazole for 8 and with penicillin G for 10 days. Within the first days after hospital admission laryngospasms, tachycardia and tachypnoe occurred. From the 7 (th) day in hospital the trismus and the cramp of the hand improved. 4 weeks after admission the patient was discharged; the trismus had completely disappeared, but a slight cramp of the hand was still present. Minor superficial injuries can lead to acute tetanus, if the level of anti-tetanus toxin-antibodies is non-protective and a disinfective wound cleaning and a postexpositional vaccination are not performed.

Production and purification of ovine anti-tetanus antibody

We used the ovine as bioreactor for the production and optimization of anti-tetanus toxin antibody. Four female sheep were immunized with human tetanus vaccine (TT-alum) every two weeks for 16 weeks, after which serum was collected and its titer was estimated by ELISA. The highest titer obtained was 39,000 IU ml-1. To optimize a purification protocol for ovine anti-tetanus toxin, we used four procedures; weak anion (DEAE-Sephadex), weak cation (CM-Sephadex), ammonium sulfate precipitation alone or in combination with caprylic acid. Fifty percent saturation with ammonium sulfate combined with caprylic acid gave us the highest yield of protein with specific activity and the purest Fab product.

Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C

In order to develop a combined recombinant Mycobacterium bovis BCG (rBCG) vaccine against diphtheria, pertussis and tetanus (DPT), we have constructed different strains of rBCG expressing tetanus toxin fragment C (FC), driven by the up-regulated M. fortuitum β-lactamase promoter, pBlaF∗. Tetanus toxin FC was expressed in comparable levels in native form or in fusion with the β-lactamase exportation signal sequence; however, in both constructs it was localized to the cytosol. Immunization of mice with rBCG-FC or its combination with rBCG expressing CRM197, induced anti-tetanus toxin antibodies with a Th2 immunoglobulin profile. Administration of a subimmunizing dose of the diphtheria–tetanus toxoid vaccine showed that rBCG-FC primed mice for production of an intense humoral response. Interestingly, the combination of rBCG-FC and rBCG-CRM197 reduced the time required for maturation of the immune response and increased anti-tetanus toxin antibody levels, suggesting adjuvant properties for rBCG-CRM197; this combination induced 75% protection in mice challenged with 100 minimum lethal doses (MLD) of tetanus toxin. Antisera from guinea pigs immunized with this combination were shown to neutralize tetanus toxin and diphtheria toxin. Our results suggest reciprocal adjuvant effects of rBCG-FC and rBCG-CRM197, which may contribute to induction of a more effective immune response against both diseases.

Rates of tetanus protection and transplacental tetanus antibody transfer in pregnant women from different socioeconomic groups in Peru.

In developing countries, neonatal tetanus causes significant mortality. Using a new competitive enzyme-linked immunosorbent assay to measure anti-tetanus toxin antibody levels, we compared rates of protection, total antibody levels, and maternal-to-fetal antibody ratios between different socioeconomic groups in Peru. Upper-middle-class women 25 years and older had significantly lower rates of protection and mean anti-tetanus toxin antibody levels than did lower-class women of the same age. Nevertheless, the former had higher fetal-to-maternal antibody ratios, independent of maternal age, total antibody levels, or parity. We conclude that future vaccination programs in Latin America must target upper-middle-class as well as lower-class women.

Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes

To establish when the formation of antibodies against T-lymphocyte-dependent and -independent antigens is impaired during HIV infection. Prospective study on antibody formation before and 30 days and 60 days after vaccination with tetravalent influenza vaccine, tetanus toxoid and pneumococcal vaccine; booster with influenza vaccine was administered 30 days after initial vaccination. Outpatient clinic of University Hospital Leiden. Fifty-one HIV-infected individuals and 10 healthy controls. In HIV-infected individuals with < 100 x 10(6)/l CD4+ lymphocytes almost no influenza antibodies were formed; CD4+ counts between 100 and 300 x 10(6)/l correlated with suboptimal antibody formation; CD4+ counts > or = 300 x 10(6)/l yielded more individuals with protective antibody titres. Thirty days after vaccination, protective antibody titres against the four influenza strains had been achieved in 24% of all HIV-infected individuals for A/Beijing (H3N2) (controls, 90%), 59% for A/Taiwan (H1N1) (controls, 80%), 18% for B/Beijing (controls, 30%) and 37% for B/Panama (controls 90%). Booster vaccination after 1 month did not increase antibody levels. Anti-tetanus toxin antibody formation, which is also T-lymphocyte-dependent, was correlated with the number of CD4+ lymphocytes. After pneumococcal vaccination (T-lymphocyte-independent), normal antibody formation was observed in HIV-infected individuals, including those with low CD4+ counts. Influenza vaccination should not be administered to HIV-infected individuals with CD4+ counts < 100 x 10(6)/l; pneumococcal vaccination can be offered to all HIV-infected individuals and a tetanus toxoid booster should be administered when indicated.

Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin.

Although tetanus and botulinum A neurotoxins are ineffective in cultured chromaffin cells, they will inhibit carbachol-induced release of noradrenaline provided they gain access to the cytosol either through artificial pores generated in the plasma membrane or by binding to incorporated exogenous gangliosides. The block of exocytosis persists for weeks followed by a slow recovery of cell function. When specific anti-botulinum A toxin antibodies are introduced into cells through pores after manifestation of the block by botulinum A neurotoxin, restoration of exocytotic function is accelerated and fully reestablished within 4 days. The same time course of restoration is seen with anti-tetanus toxin antibodies in cells poisoned by tetanus toxin. Since the light chains of the toxins are enzymatically active, we have introduced polyclonal and monoclonal anti-light chain antibodies into the cytosol. Of all light chain antibodies tested, only those directed against the peptide homologous to the zinc-binding sequence, which is present in both neurotoxins, restored exocytosis regardless of which toxin caused the block. These results indicate that the zinc-binding domain is directly involved in the interaction of the light chains with their substrates and that the toxins have to be present continuously to maintain the block.

Restoration of exocytosis occurs after inactivation of intracellular tetanus toxin

Tetanus toxin blocks carbachol-stimulated release of noradrenaline from bovine adrenal chromaffin cells in culture, provided it can gain access to the cells. This can be achieved by electropermeabilization of the plasma membrane or by enriching the membrane with exogenous gangliosides which serve as carriers of the toxin. The inhibition of noradrenaline release persists for at least 6 days, even in the presence of specific anti-tetanus toxin antibodies in the culture medium. However, the block is preventable, for the most part, when antibodies enter chromaffin cells during electropermeabilization, before the uptake of the toxin is facilitated by inserting exogenous gangliosides into the plasma membrane 2 days later. This indicates that the antibodies pass into the cells through the physically induced pores and that these intracellular antibodies neutralize incoming tetanus toxin. If, on the other hand, exocytosis has been inhibited by tetanus toxin, it will recover within 3 days, provided specific anti-tetanus toxin antibodies are introduced into the cells by electropermeabilization. The recovery is not linked to a specific route of entry of the toxin. It is concluded that the restoration of noradrenaline release requires not only the intracellular neutralization of tetanus toxin but also the reconstitution of the as yet unknown target molecule of the toxin.

Tetanus toxin-[2,3-3H]propionamid. Synthesis, specific activity, immunoreactivity, toxicity and ascent into the spinal cord.

Tetanus toxin was tritiated with various amounts of N-succinimidyl-[2,3-3H]propionate. A tenfold molar excess of reagent over toxin was used for the introduction of about 5 nmol of [2,3-3H]propionate into 1 nmol of toxin, corresponding to a specific activity of about 48 MBq/mg protein. The labelling procedure did not change significantly the immunoreactivity of tetanus toxin, but reduced the toxicity in mice from 12 ng/kg to 16 ng/kg. Tetanus toxin-[2,3-3H]propionamid was carried through the peripheral nerves into the spinal cord. It could be used instead of 125I-labelled toxin for the detection of anti-tetanus toxin antibodies with a detection limit of 0.25 mU/ml of serum.

Protective human hybridoma antibody to tetanus toxin.

Postimmunization human B lymphocytes and mouse myeloma cells were fused to produce interspecies hybridomas secreting human antibody of predefined specificity with an initial frequency comparable to intraspecies fusion. After 13 mo in culture, one clone continued to secrete high titers of human IgG antitetanus toxin antibody. This antibody binds to the B fragment of tetanus toxin and protects mice against tetanus. The demonstration of in vivo protection with a human monoclonal antibody is an important first step towards the ultimate goal of human administration of monoclonal antibodies for the prevention and therapy of human infections.

Screening for anti-tetanus toxin antibodies in Iran

Une approche préliminaire de dépistage des anticorps antitétaniques a été réalisée avec succès sur un Groupamatic 360 C, à partir de la technique développée et utilisée au C.N.T.S. à Paris. Nous décrivons ici la préparation du réactif et présentons les premiers résultats, en les comparant avec des chiffres obtenus antérieurement en utilisant une technique d'immunodiffusion radiale.